Related Experiment Videos
Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M).
M Morfini1, G Longo, A Messori
1Hematology Department and Hemophilia Center, University of Florence, Italy.
Abstract:
A recombinant FVIII preparation, Recombinate, was compared with a high-purity plasma-derived concentrate, Hemofil M, in 47 hemophilia A patients in a cross-over evaluation of pharmacokinetic properties. The recombinant material showed a significantly lower clearance, volume of distribution, and higher in vivo recovery, but a similar half-life to the plasma-based product. In a comparison with reported data from other standard concentrates, the recombinant preparation exhibited potentially better pharmacokinetic properties in that its clearance was slower and its half-life was longer. We conclude that the recombinant DNA method of preparation does not adversely affect the biological and pharmacological characteristics of the factor VIII molecule.
Insights
Recombinant Factor VIII (FVIII) showed improved pharmacokinetic properties compared to plasma-derived FVIII in hemophilia A patients. This suggests recombinant DNA methods do not harm FVIII
Area of Science:
- Hematology
- Pharmacology
- Biotechnology
Background:
- Hemophilia A is a genetic bleeding disorder caused by a deficiency in Factor VIII (FVIII).
- Plasma-derived FVIII concentrates have been the standard treatment, but recombinant FVIII offers an alternative.
- Understanding the pharmacokinetic properties of recombinant FVIII is crucial for optimizing patient care.
Purpose of the Study:
- To compare the pharmacokinetic properties of a recombinant FVIII preparation (Recombinate) with a high-purity plasma-derived FVIII concentrate (Hemofil M).
- To evaluate if the recombinant DNA method of preparation impacts the biological and pharmacological characteristics of FVIII.
Main Methods:
- A cross-over study involving 47 hemophilia A patients.
- Pharmacokinetic analysis including clearance, volume of distribution, in vivo recovery, and half-life was performed for both FVIII preparations.
- Comparison of recombinant FVIII data with reported data from other standard concentrates.
Main Results:
- Recombinant FVIII exhibited significantly lower clearance and volume of distribution compared to Hemofil M.
- In vivo recovery was higher for recombinant FVIII, while half-life was similar between the two products.
- Compared to other standard concentrates, recombinant FVIII showed potentially superior pharmacokinetic properties (slower clearance, longer half-life).
Conclusions:
- The recombinant DNA method of preparation does not adversely affect the biological and pharmacological characteristics of the FVIII molecule.
- Recombinant FVIII demonstrates favorable pharmacokinetic properties, potentially offering advantages over plasma-derived concentrates.
- These findings support the use of recombinant FVIII in hemophilia A management.